Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand’s PHARMAC Declines Funding For Roche’s Herceptin 12-Month Treatment For Early HER2 Positive Patients

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - New Zealand's Pharmaceutical Management Agency has decided to decline funding for Roche's Herceptin (trastuzumab) for 12-month treatment for HER2-positive early breast cancer treatment, the agency announced Aug. 7
Advertisement

Related Content

New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis
PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis
Advertisement
UsernamePublicRestriction

Register

SC069251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel